The unexpected therapeutic effects of CXCR2 CAR-T in the PDAC liver metastasis model may be due to the more exposed recognition of CXCL5 in metastatic tumors compared to the shielding of the stroma structure in primary tumors. Here, CXCL5 is linked to metastatic neoplasm.